The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
General Updates | Recent advances in eosinophilia with FGFR rearrangement
Jean-Jacques Kiladjian, MD, PhD, Saint-Louis Hospital & Paris Diderot University, Paris, France, gives an update on the management of eosinophilia with fibroblast growth factor receptor (FGFR) rearrangement. Encouraging results from the FIGHT-203 study (NCT03011372) evaluating pemigatinib are expected to improve the outcomes of this patient population. This interview took place virtually.
Disclosures
Advisory boards for Novartis, Abbvie, BMS, AOP Orphan.
